Table 1

Baseline characteristics of the OCT DES trial

ZESEESP value
(n=30)(n=30)
Age (years)62.6±12.0159.20±9.810.2345
Sex (male/female)23/722/80.7656
Ethnicity (Caucasian), n (%)15 (50%)14 (46.7%)0.7961
Ethnicity (Asian), n (%)14 (46.7%)14 (46.7%)>0.9999
Acute Coronary Syndrome (non-ST-elevation myocardial infarction)/stable10/2013/170.5959
Medical history
 Hypertension (%)25 (83.3%)26 (86.7%)0.7177
 Hypercholesterolaemia (%)23 (76.7%)22 (73.3%)0.7656
 Type 2 diabetes mellitus (%)15 (100%)15 (100%)>0.9999
 Active smoker (%)7 (23.3%)3 (10%)0.1659
 Previous myocardial infarction (%)11 (36.7%)12 (40%)0.7906
 Family history (%)8 (26.7%)7 (23.3%)0.7656
Medical therapy
 Aspirin (%)15 (100%)15 (100%)>0.9999
 Clopidogrel (%)18 (60%)16 (53.3%)0.6023
 Statin (%)28 (93.3%)27 (90%)0.6404
 ACEi (%)21 (70%)18 (60%)0.4168
 β-Blockers (%)22 (73.3%)23 (76.7%)0.7656
Diabetes therapy
 Diet control1 (3.3%)2 (6.7%)0.5923
 Oral antiglycaemics20 (66.7%)22 (73.3%)0.5731
 Combined insulin therapy9 (30%)6 (20%)0.3711
 Baseline haemoglobin A1c IFCC (20–48)62.4±17.461.8±17.90.9137
Symptoms
 New York Heart Association1.70±0.601.83±0.910.5056
 Canadian Cardiovascular Society1.77±0.732.00±0.710.2170
Baseline observations
 Pulse (bpm)67.07±11.6467.57±11.890.8709
 Systolic blood pressure (mm Hg)130.7±17.63131.0±24.410.9541
 Diastolic blood pressure (mm Hg)67.26±8.6969.61±9.500.3439
Vessel treated0.2242
 LAD16 (53.3%)18 (60%)
 LCx6 (20%)9 (30%)
 RCA8 (26.7%)3 (10%)
 Multivessel PCI4 (13.3%)6 (20%)0.4884
  • Plus-minus values are mean±SD.

  • Vessels treated P value assessed by χ2 test.

  • ACEi, ACE inhibitor; DES, drug-eluting stent; EES, everolimus-eluting stent; LAD, left anterior descending; LCx, left circumflex; n, number; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; RCA, right coronary artery; ZES, zotarolimus-eluting stent.